Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

No compulsory genetic testing for newborn babies in Europe

01.07.2004


European Research Commissioner Philippe Busquin today rejected stories in several media claiming he had called for genetic testing of all newborn babies in Europe. Mr Busquin said: “I have never advocated any such point of view. It is not the role nor the intention of the Commission to ask EU Member States to impose universal genetic screening of babies. Genetic testing is a matter of free choice and of ethical rules being decided by EU Member States. The Commission does not regulate ethics. I certainly welcome the contribution of the expert group on genetic testing which presented its report to the Commission on May 6-7, 2004. But its recommendations are simple suggestions – and they don’t call for universal genetic testing of babies! Genetic testing can certainly help in the early detection of illnesses, but can never be made compulsory. European citizens rightly expect that the results of genetic tests are reliable and that their genetic information is used properly and following strict quality and ethical standards. The Commission is in particularly studying the issue of quality and reliability of this new technology, that must be used in a responsible and voluntary way and in a climate of confidence with the public at large.”

Independent advice

On December 2002, the European Commission established an expert group to address the ethical, legal and social implications of genetic testing. The Group included representatives from NGOs (including patient organisations), pharmaceutical companies (GSK, Roche, Novartis, Bayer, Genzyme), scientists and representatives from academia specialising in law, philosophy, ethics and medicine. The Group was acting in full autonomy and independence. It prepared a report and 25 recommendations on the ethical, legal and social implications of genetic testing. They only reflect the views of the expert group’s members and are not legally binding.



Free choice

The recommendations were presented and discussed at a conference on May 6-7, 2004. The expert group stated that: “genetic testing is a matter of free choice and it is never to be imposed”. As far as the use of genetic tests for rare diseases is concerned, the expert group suggested that for “rare but serious diseases for which treatment is available, Member States should introduce universal neonatal screening as a priority”. The Group is therefore not asking the European Commission nor Member States to launch any global post-natal genetic screening programme but to consider screening only for rare and serious diseases for which treatments already exist.

Ban on eugenics

The ban of eugenic practices is stated in Art.3 d of the European Charter of Fundamental Rights, approved by the Nice Summit in 2002, and recently included in the Constitutional Treaty for Europe approved by the Council in June 2004: “In the field of medicine and biology the following principles must be respected: (…) the prohibition of eugenic practices, in particular those aiming at the selection of persons (Article II-3)”.

Responsible use

Commissioner Busquin welcomes the work of the expert group in approaching the ethical, legal and social implications of genetic testing. This effort may be beneficial for a responsible use of this technology which represents progress in healthcare and preventive medicine. Any use of genetic tests which would contradict the Fundamental Rights stated in the European Charter, would not be supported by the Commission, as well any proposal which would contradict the principle of subsidiarity and the autonomy of Member States on ethical issues.

Fabio Fabbi | EU Commission
Further information:
http://europa.eu.int
http://europa.eu.int/comm/research/conferences/2004/genetic/index_en.htm

More articles from Life Sciences:

nachricht Molecular Force Sensors
20.09.2017 | Max-Planck-Institut für Biochemie

nachricht Foster tadpoles trigger parental instinct in poison frogs
20.09.2017 | Veterinärmedizinische Universität Wien

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Molecular Force Sensors

20.09.2017 | Life Sciences

Producing electricity during flight

20.09.2017 | Power and Electrical Engineering

Tiny lasers from a gallery of whispers

20.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>